Melanoma & Skin Cancer

January 11, 2021 — The FDA has granted an orphan drug designation to the novel intratumoral immunotherapy agent PVSRIPO for the treatment of patients with advanced melanoma, specifically those with stage IIIB-IV disease.

Mario Sznol, MD, discusses toxicities associated with immunotherapy in patients with melanoma.

Jason J. Luke, MD, FACP, compares predictive and prognostic biomarkers in melanoma.

The small interfering RNA therapeutic STP705 has been found to induce high rates of histological clearance with a favorable toxicity profile in patients with squamous cell skin cancer.

Although basal cell carcinoma generally has a good prognosis, improving tolerance to targeted Hedgehog inhibitors and optimizing second-line treatment with immune checkpoint inhibitors are important for the small subset of patients who develop locally advanced or metastatic disease.

Mario Sznol, MD, discusses the challenges of managing immune-related toxicities in melanoma.

December 16, 2020 — The combination of nivolumab with ipilimumab demonstrated activity in patients with metastatic uveal melanoma with encouraging responses.

Michael B. Atkins, MD, discusses the benefits of neoadjuvant therapy in melanoma.

Ryan Sullivan, MD, discusses treatment options in BRAF-mutant melanoma.

Mario Sznol, MD, discusses the critical importance of being aware of the immune-related toxicities that could arise when treating patients with cancer, along with the best ways to manage them.

Jeffrey S. Weber, MD, PhD, discusses unmet needs in melanoma.